Drug General Information
Drug ID	D00YDN
Former ID	DIB014242
Drug Name	CXR-1002
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[549291]
Company	CXR Biosciences Ltd
Structure		Download 2D MOL 3D MOL
Canonical SMILES	C(C(C(C(C(=O)O)(F)F)(F)F)(F)F)(C(C(C(F)(F)F)(F)F)(F)F)(<br />F)F.N
Target and Pathway
Target(s)	Proto-oncogene pim-1	Target Info	Inhibitor	[551578]
KEGG Pathway	Jak-STAT signaling pathway
	MicroRNAs in cancer
	Acute myeloid leukemia
NetPath Pathway	IL9 Signaling Pathway
	IL5 Signaling Pathway
	IL2 Signaling Pathway
	TGF_beta_Receptor Signaling Pathway
	TCR Signaling Pathway
Pathway Interaction Database	GMCSF-mediated signaling events
	Validated targets of C-MYC transcriptional activation
	Role of Calcineurin-dependent NFAT signaling in lymphocytes
	IL5-mediated signaling events
	IL3-mediated signaling events
	C-MYB transcription factor network
WikiPathways	Ectoderm Differentiation
	Hematopoietic Stem Cell Differentiation
References
Ref 549291	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034732)
Ref 551578	123 Antitumor activity of CXR1002, a novel anti-cancer clinical phase compound that induces ER stress and inhibits PIM kinases: Human tumor xenograft efficacy and in vitro mode of action. EJC Supplements, 2010; 8(7):45-46.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.